Enliven Therapeutics, Inc. Share Price

Enliven Therapeutics, Inc. Share Price

NASDAQ: ELVN | Mid Cap
$46.84
-$0.73 (-1.52%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Enliven Therapeutics, Inc. Stock Performance

Open
$47.17
Prev. Close
$47.57
Circuit Range
N/A
Day Range
$46.22 - $47.44
Year Range
$14.84 - $61.85
Volume
26,946
Average Traded
$46.81

Enliven Therapeutics, Inc. Share Price Today

As of 18 November 2026, Enliven Therapeutics, Inc.'s share price is $46.84. The stock opened at $47.17, compared to its previous close of $47.57. During today's trading session, Enliven Therapeutics, Inc.'s share price traded between $46.22 and $47.44, with an average price of $46.83. Over the past 52 weeks, the stock has recorded a high of $61.85 and a low of $14.84. In terms of performance, Enliven Therapeutics, Inc.'s share price has risen by 18.28% over the last six months and is up 116.87% on a year-on-year basis.

Enliven Therapeutics, Inc. Share Price Chart

Line chart of the Enliven Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 46.04 to 47.74, ending at 46.84.
$46.22$47.44
L
Show Current Price
H

Enliven Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$2.65B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.54
Revenue (TTM)
$0.00
Return On Equity (TTM)
-12.94%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
6.64%

Enliven Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$29.67-$23.63-$32.49-$27.70
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A20.36%-37.49%14.74%

Enliven Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.00$0.00
Net Profit-$71.58-$89.02-$103.69
Net Profit MarginN/AN/AN/A
Income ChangeN/A-24.36%-16.48%

About Enliven Therapeutics, Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$44.16
$46.78
+5.57%
Oct 2026
$45.79
$44.31
-3.42%
Sep 2026
$57.93
$45.88
-24.15%
Aug 2026
$53.50
$60.48
+10.43%
Jul 2026
$51.27
$54.77
+7.92%
Jun 2026
$38.73
$50.75
+28.14%
May 2026
$40.73
$39.60
-4.00%
Apr 2026
$39.57
$41.26
+5.43%
Mar 2026
$29.48
$39.13
+31.80%
Feb 2026
$26.25
$29.69
+12.00%
Jan 2026
$15.34
$26.51
+72.25%
Dec 2025
$20.78
$15.39
-28.75%

ELVN Share Price FAQs